Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Interchangeability, immunogenicity and biosimilars

Nature Biotechnology volume 30, pages1186–1190(2012)Cite this article

Subjects

For authorized biosimilars to achieve full acceptance in the marketplace, it is crucial that they are considered to be therapeutically equivalent and interchangeable with the brand reference product.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

References

  1. 1

    European Commission. Off. J. Eur. Union L136, 34–57 (2004).

  2. 2

    Health, I.M.S. Shaping the Biosimilars Opportunity: a Global Perspective on the Evolving Biosimilars Landscape (IMS Health, New York, USA, 2011; accessed 11 April 2012). <http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf>

    Google Scholar 

  3. 3

    European Medicines Agency. Volume 9A of The Rules Governing Medicinal Products in the European Union. (EMA, London, 2008; accessed 2 August 2012). <http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf>

  4. 4

    European Commission. Off. J. Eur. Union L311, 67–267 (2001).

  5. 5

    European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (EMA, London, 2007; accessed 3 July 2012). <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003947.pdf>

  6. 6

    Casadevall, N. et al. N. Engl. J. Med. 346, 469–475 (2002).

    CAS  Article  Google Scholar 

  7. 7

    Gascon, P. et al. Ann. Oncol. 21, 1419–1429 (2010).

    CAS  Article  Google Scholar 

  8. 8

    European Medicines Agency. EPARs for Authorised Medicinal Products for Human Use (EMA, London; accessed 9 September 2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124

  9. 9

    Frau, S., Font Pous, M., Luppino, M.R. & Conforti, A. Eur. J. Clin. Pharmacol. 66, 785–790 (2010).

    CAS  Article  Google Scholar 

  10. 10

    Haag-Weber, M. et al. Clin. Nephrol. 77, 8–17 (2012).

    CAS  Article  Google Scholar 

  11. 11

    Seidl, A. et al. Pharm. Res. 29, 1454–1467 (2012).

    CAS  Article  Google Scholar 

  12. 12

    Jiang, Y. et al. J. Pharm. Sci. 98, 4695–4710 (2009).

    CAS  Article  Google Scholar 

  13. 13

    Praditpornsilpa, K. et al. Kidney Int. 80, 88–92 (2011).

    CAS  Article  Google Scholar 

  14. 14

    Peterson, G.M. Br. J. Clin. Pharmacol. 71, 966–967, author reply 968 (2011).

    Article  Google Scholar 

  15. 15

    Meredith, P.A. Curr. Med. Res. Opin. 25, 2179–2189 (2009).

    CAS  Article  Google Scholar 

  16. 16

    Walsh, G. Drug Discov. Today 15, 773–780 (2010).

    CAS  Article  Google Scholar 

  17. 17

    European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues EMEA/CHMP/BMWP/42832/2005 (EMA, London, 2006; accessed 26 July 2012). <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf>

  18. 18

    European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (EMA, London, 2006). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf

  19. 19

    Covic, A. et al. Nephrol. Dial. Transplant. 23, 3731–3737 (2008).

    Article  Google Scholar 

  20. 20

    Rovira, J., Espin, J., Garcia, L. & Olry de Labry, A. The Impact of Biosimilars' Entry in the EU Market (Andalusian School of Public Health, Spain, 2011).

    Google Scholar 

  21. 21

    Niederwieser, D. & Schmitz, S. Eur. J. Haematol. 86, 277–288 (2011).

    CAS  Article  Google Scholar 

  22. 22

    Minghetti, P., Rocco, P., Del Vecchio, L. & Locatelli, F. Nephron Clin. Pract. 117, c1–c7 (2011).

    CAS  Article  Google Scholar 

  23. 23

    Brinks, V. et al. Pharm. Res. 28, 386–393 (2011).

    CAS  Article  Google Scholar 

  24. 24

    Storring, P.L. et al. Br. J. Haematol. 100, 79–89 (1998).

    CAS  Article  Google Scholar 

  25. 25

    Schiestl, M. et al. Nat. Biotechnol. 29, 310–312 (2011).

    CAS  Article  Google Scholar 

  26. 26

    Vanrenterghem, Y. et al. Kidney Int. 62, 2167–2175 (2002).

    CAS  Article  Google Scholar 

  27. 27

    Dellanna, F. et al. Int. J. Clin. Pract. 65, 64–72 (2011).

    CAS  Article  Google Scholar 

  28. 28

    Ebbers, H.C., Muenzberg, M. & Schellekens, H. Exp. Opin. Biol. Ther. 12, 1473–1485 (2012).

    CAS  Article  Google Scholar 

  29. 29

    Duerden, M.G. & Hughes, D.A. Br. J. Clin. Pharmacol. 70, 335–341 (2010).

    Article  Google Scholar 

  30. 30

    Kresse, G.B. Eur. J. Pharm. Biopharm. 72, 479–486 (2009).

    CAS  Article  Google Scholar 

  31. 31

    Declerck, P.J. et al. Curr. Med. Res. Opin. 26, 1219–1229 (2010).

    CAS  Article  Google Scholar 

  32. 32

    Shankar, G., Pendley, C. & Stein, K.E. Nat. Biotechnol. 25, 555–561 (2007).

    CAS  Article  Google Scholar 

  33. 33

    Macdougall, I.C. et al. N. Engl. J. Med. 361, 1848–1855 (2009).

    CAS  Article  Google Scholar 

  34. 34

    European Medicines Agency. Scientific Guidance Documents on Biosimilar Medicines (EMA, London; accessed 4 September 2012) <http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac058002958c&jsenabled=true>

Download references

Author information

Affiliations

  1. Hans C. Ebbers is in the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.

    Hans C Ebbers

  2. Stacy A. Crow and Arnold G. Vulto are in the Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands

    Stacy A Crow & Arnold G Vulto

  3. Huub Schellekens is at the Copernicus Institute/Department of Innovation and Environmental Studies, and the Department of Pharmaceutics, UIPS, Utrecht University, Utrecht, The Netherlands.

    Huub Schellekens

Authors
  1. Hans C Ebbers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stacy A Crow
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arnold G Vulto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huub Schellekens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans C Ebbers.

Ethics declarations

Competing interests

The authors declare no conflict of interest relevant to the subject matter or materials discussed in the manuscript. No funding was received for the preparation of this article. This study was performed in the context of the Escher project (T6-202), a project of the Dutch Top Institute Pharma. The division of Pharmacoepidemiology and Clinical Pharmacology, where H.C.E. is employed, has received unrestricted funding for pharmaco-epidemiological research from GlaxoSmithKline, the private-public funded Top Institute Pharma (http://www.tipharma.nl, includes co-funding from universities, government and industry), the Dutch Medicines Evaluation Board and the Dutch Ministry of Health. H.S. participated in meetings and publications sponsored by Amgen, Johnson & Johnson, Roche, Sandoz and Hospira. Part of his research is directly or indirectly sponsored by Roche, Amgen and Sandoz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ebbers, H., Crow, S., Vulto, A. et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 30, 1186–1190 (2012). https://doi.org/10.1038/nbt.2438

Download citation

Further reading

  • Switching from originator recombinant growth hormone (Genotropin™) to biosimilar (CRISCY™): Results from a 6-month, multicentric, non-inferiority, extension trial.

    • M.A. Czepielewski
    • , Q. Garret
    • , S.A.C. Vencio
    • , N. Rassi
    • , M.S. Faria
    • , C.C.P. Senn
    • , M.D. Bronstein
    • , M.J.A.G. Cerqueira
    • , A.C.L. Neves
    • , A.M. Spinola-Castro
    • , M.P.R. Cunha
    • , N.R. Leite
    • , G.E. Wassermann
    • , M.C. Alegria
    • , O. Toffoletto
    • , J. Afiune
    • , R. Baradelli
    • , D.G. Rodrigues
    •  & M. Scharf

    Growth Hormone & IGF Research (2021)

  • Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences

    • Daan J.A. Crommelin
    • , Enrico Mastrobattista
    • , Andrea Hawe
    • , Karin H. Hoogendoorn
    •  & Wim Jiskoot

    Journal of Pharmaceutical Sciences (2020)

  • The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease

    • Guillermo Drelichman
    • , Gilberto Castañeda‐Hernández
    • , Muhlis Cem Ar
    • , Marta Dragosky
    • , Ricardo Garcia
    • , Howard Lee
    • , Sergey Moiseev
    • , Majid Naderi
    • , Hanna Rosenbaum
    • , Irena Žnidar
    • , Andrés Felipe Zuluaga
    • , Selena Freisens
    •  & Pramod K. Mistry

    American Journal of Hematology (2020)

  • Report on the Second PANLAR Review Course in Rheumatology

    • Carlos Vinicius Caballero-Uribe
    • , Valderilio Feijó Azevedo
    • , Enrique Roberto Soriano
    • , Carlos Pineda
    • , Claudio Galarza-Maldonado
    • , Igor Age Kos
    •  & Osvaldo Castañeda Jimenez

    JCR: Journal of Clinical Rheumatology (2020)

  • Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass Spectrometry

    • Kristina Srzentić
    • , Luca Fornelli
    • , Yury O. Tsybin
    • , Joseph A. Loo
    • , Henrique Seckler
    • , Jeffrey N. Agar
    • , Lissa C. Anderson
    • , Dina L. Bai
    • , Alain Beck
    • , Jennifer S. Brodbelt
    • , Yuri E. M. van der Burgt
    • , Julia Chamot-Rooke
    • , Sneha Chatterjee
    • , Yunqiu Chen
    • , David J. Clarke
    • , Paul O. Danis
    • , Jolene K. Diedrich
    • , Robert A. D’Ippolito
    • , Mathieu Dupré
    • , Natalia Gasilova
    • , Ying Ge
    • , Young Ah Goo
    • , David R. Goodlett
    • , Sylvester Greer
    • , Kim F. Haselmann
    • , Lidong He
    • , Christopher L. Hendrickson
    • , Joshua D. Hinkle
    • , Matthew V. Holt
    • , Sam Hughes
    • , Donald F. Hunt
    • , Neil L. Kelleher
    • , Anton N. Kozhinov
    • , Ziqing Lin
    • , Christian Malosse
    • , Alan G. Marshall
    • , Laure Menin
    • , Robert J. Millikin
    • , Konstantin O. Nagornov
    • , Simone Nicolardi
    • , Ljiljana Paša-Tolić
    • , Stuart Pengelley
    • , Neil R. Quebbemann
    • , Anja Resemann
    • , Wendy Sandoval
    • , Richa Sarin
    • , Nicholas D. Schmitt
    • , Jeffrey Shabanowitz
    • , Jared B. Shaw
    • , Michael R. Shortreed
    • , Lloyd M. Smith
    • , Frank Sobott
    • , Detlev Suckau
    • , Timothy Toby
    • , Chad R. Weisbrod
    • , Norelle C. Wildburger
    • , John R. Yates
    • , Sung Hwan Yoon
    • , Nicolas L. Young
    •  & Mowei Zhou

    Journal of the American Society for Mass Spectrometry (2020)

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing